Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cellsBrian J. Morrison, John C. Morris|BMC Cancer|2018Cited by 131
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and NeckRobert L. Ferris, Ezra E.W. Cohen, Nabil F. Saba et al.|JAMA Oncology|2018Cited by 111
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical EfficacyHoyoung Maeng, Jay A. Berzofsky, Vandana Sachdev et al.|Frontiers in Oncology|2021Cited by 26
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).Hoyoung Maeng, Jay A. Berzofsky, Lauren V. Wood et al.|Journal of Clinical Oncology|2019Cited by 8
Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid TumorsNagla Abdel Karim, John C. Morris|Asian Pacific Journal of Cancer Prevention|2019Cited by 6